Turkey Restructures Reimbursement Body But Is It Enough?

This article was originally published in PharmAsia News

14 Mar 2016
News

Ahmet Sevindik

Executive Summary

Turkey has designated health sciences, and the pharmaceutical industry in particular, as a strategic sector to support economic development, and the government appears determined to turn the country into a regional hub by supporting production and high-value exports. The national reimbursement body has recently been restructured to promote these goals but the industry is cautious.

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

Topics

Turkey

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Turkey Business Strategies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC089360

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC089360

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Turkey Restructures Reimbursement Body But Is It Enough?

News

Executive Summary

Related Content

Turkey Fighting Uphill Battle In Pitch For Pharma, Medtech Investment

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert